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Abstract
BACKGROUND—To estimate the frequency and duration of detectable Zika virus (ZIKV) RNA 
in human body fluids, we prospectively assessed a cohort of newly infected participants in Puerto 
Rico.
METHODS—We evaluated samples obtained from 150 participants (including 55 men) in whom 
ZIKV RNA was detected on reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay in 
urine or blood in an enhanced arboviral clinical surveillance site. We collected serum, urine, 
saliva, semen, and vaginal secretions weekly for the first month and then at 2, 4, and 6 months. All 
specimens were tested by means of RT-PCR, and serum was tested with the use of anti–ZIKV IgM 
enzyme-linked immunosorbent assay. Among the participants with ZIKV RNA in any specimen at 
week 4, biweekly collection continued until all specimens tested negative. We used parametric 
Weibull regression models to estimate the time until the loss of ZIKV RNA detection in each body 
fluid and reported the findings in medians and 95th percentiles.
RESULTS—The medians and 95th percentiles for the time until the loss of ZIKV RNA detection 
were 14 days (95% confidence interval [CI], 11 to 17) and 54 days (95% CI, 43 to 64), 
respectively, in serum; 8 days (95% CI, 6 to 10) and 39 days (95% CI, 31 to 47) in urine; and 34 
days (95% CI, 28 to 41) and 81 days (95% CI, 64 to 98) in semen. Few participants had detectable 
ZIKV RNA in saliva or vaginal secretions.
CONCLUSIONS—The prolonged time until ZIKV RNA clearance in serum in this study may 
have implications for the diagnosis and prevention of ZIKV infection. Current sexual-prevention 
guidelines recommend that men use condoms or abstain from sex for 6 months after ZIKV 
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exposure; in 95% of the men in this study, ZIKV RNA was cleared from semen after about 3 
months. (Funded by the Centers for Disease Control and Prevention.)
After its discovery in uganda in 1947, Zika virus (ZIKV) was identified in Brazil in 2015 
and subsequently spread throughout the Americas.1 ZIKV is now recognized as a cause of 
congenital neurologic birth defects, notably microcephaly,2 and has been associated with 
potentially fatal complications.3,4
ZIKV infection can be diagnosed through detection of ZIKV RNA in blood, urine, and other 
body fluids on reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay.5 However, 
the frequency with which ZIKV RNA can be detected in various body fluids and the length 
of time that it remains detectable are not well understood. Similarly, ZIKV infection can also 
be diagnosed by the detection of anti–ZIKV IgM antibodies, although the kinetics of IgM 
antibody production have not been fully described.
Although most ZIKV infections are probably transmitted by infected mosquitoes, ZIKV 
transmission has been documented through sexual contact,6 blood transfusion,7 laboratory 
exposure,1 and both intrauterine and intrapartum transmission.8 ZIKV RNA has been 
detected in semen,9 urine,10 saliva,11 cerebrospinal fluid,12 vaginal or cervical secretions,
13,14
 and other body fluids.15-18 Most transmissions through sexual contact have been from 
men with symptomatic infection to their female partners.19-21 However, sexual transmission 
has also occurred from asymptomatic men,22,23 through male-to-male24 and female-to-male 
sex,25 and possibly through oral sex.9 Shedding in the female genital tract appears to be rare 
and of short duration.13 In contrast, there are reports of prolonged detection of ZIKV RNA 
in semen, with the longest reported duration of detection up to 188 days after onset.26,27 
Infectious virus has been reported in semen up to 69 days.28
A detailed understanding of the dynamics of the early stages of ZIKV infection is needed to 
inform diagnostic testing algorithms and prevention interventions, since existing evidence is 
based on case reports and cross-sectional observations, primarily from returning travelers.29 
To estimate the presence and duration of the detection of ZIKV RNA in body fluids and 
anti–ZIKV IgM antibody among participants with acute ZIKV infection, we established the 
ZIKV Persistence (ZiPer) cohort study in Puerto Rico, in which we prospectively evaluated 
multiple concurrently collected specimens from participants. Here, we report the results of 
the interim analyses to provide timely data that can inform recommendations.
METHODS
STUDY DESIGN AND OVERSIGHT
ZiPer is a prospective cohort study involving participants of all ages with ZIKV infection, as 
diagnosed by means of RT-PCR, with a target enrollment of 350 participants. Beginning in 
May 2016, participants were identified through the Sentinel Enhanced Dengue Surveillance 
System (SEDSS), a prospective surveillance of acute febrile illness among patients 
presenting to the emergency department of a tertiary care hospital or an outpatient clinic, 
both located in Ponce, Puerto Rico. Patients who presented with fever (temperature, ≥38.0°C 
[100.5°F]), rash, conjunctivitis, or arthralgia were offered participation in SEDSS. Among 
Paz-Bailey et al. Page 2
N Engl J Med. Author manuscript; available in PMC 2018 August 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the participants who provided written informed consent, blood and urine specimens were 
tested for causative agents of acute febrile illness, including ZIKV. SEDSS participants who 
tested positive for ZIKV infection on RT-PCR (index participants) were systematically 
contacted by study staff and were offered enrollment in ZiPer. The household members of 
index participants were invited to participate and provide specimens, and those who tested 
positive on RT-PCR joined the prospective cohort study. Full details regarding the study 
design are provided in the protocol (available with the full text of this article at NEJM.org), 
which was reviewed and approved by the institutional review boards at the Centers for 
Disease Control and Prevention (CDC) and Ponce Health Sciences University.
PROCEDURES
All the participants completed an interviewer-administered questionnaire, which included 
reporting the number of days that had elapsed since the onset of ZIKV symptoms; household 
contacts of the participants reported such data at the time of enrollment. Participants were 
defined as being symptomatic if they reported having had signs or symptoms of ZIKV 
infection (fever, conjunctivitis, rash, or arthralgia) during the 30 days before the interview. 
Serum, urine, saliva, semen, and vaginal secretions (the last two in adults only) were 
collected weekly for the first month and at 2, 4, and 6 months thereafter. Among the 
participants in whom ZIKV RNA was detected in any specimen at week 4, biweekly 
collection continued until all the specimens tested negative. (Details are provided in the 
Methods section in the Supplementary Appendix, available at NEJM.org.) All the 
participants received a $50 reimbursement per visit.
LABORATORY TESTING
Specimens were tested by means of the Trioplex RT-PCR assay, as recommended by the 
CDC for the detection of dengue, chikungunya, and ZIKV RNA.30 In addition, we 
performed validation analyses for the use of the Trioplex RT-PCR assay in semen (see the 
Supplementary Appendix). Specimens were considered to be positive if target amplification 
was detected within 38 threshold cycles. The RNA extraction and real-time RT-PCR process 
were considered to be valid if the human RNase P reaction was positive. Intermittent RNA 
detection was defined as the detection of viral RNA that was followed by a lack of detection 
and then subsequent detection, regardless of the interval between specimen collections. 
Serum was tested by means of anti–ZIKV IgM antibody capture enzyme-linked 
immunosorbent assay.31 ZIKV isolation was attempted through culture in a subset of semen 
and serum specimens (see the Supplementary Appendix).
STATISTICAL ANALYSIS
We summarized the demographic and clinical characteristics of the participants, along with 
details regarding the detection of ZIKV RNA in fluids and IgM antibody according to the 
number of days that had elapsed since the onset of ZIKV symptoms. We used the kappa 
statistic to assess the beyond-chance agreement in RNA detection in paired samples of 
semen and serum and in paired samples of semen and urine obtained from male participants. 
Since all the participants had positive results on testing of serum or urine at enrollment, we 
could not independently assess the serum–urine agreement. The time until the loss of RNA 
detection in each fluid was defined as the number of days between the onset of ZIKV 
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symptoms and the first negative RT-PCR result. To estimate model-derived percentiles for 
the time until virus clearance at the population level, we assumed that all infected 
participants had ZIKV RNA in all specimens at symptom onset. For the participants who 
had intermittent shedding of ZIKV, we used the first negative result after the final recorded 
test result that was positive on RT-PCR; data were censored for the participants who still had 
positive results on RT-PCR at the time of the analysis.
The time until the detection of IgM antibody was defined as the number of days between the 
onset of ZIKV symptoms and the first IgM-positive result; data were censored for the 
participants in whom the results were still IgM-negative at the time of the analysis. We used 
the Kaplan–Meier method to estimate survival functions for these outcomes, along with the 
non-parametric maximum-likelihood Turnbull estimator and parametric Weibull regression 
models. (Details about these models are provided in the Supplementary Appendix.) The 
Turnbull method and Weibull models accounted for interval censoring (since the loss of 
detection of ZIKV RNA occurred within an interval between visits instead of being observed 
on an exact date). From the Weibull models, we estimated survival functions and their 95% 
confidence intervals, as well as medians and 95th percentiles. In supplementary analyses, we 
estimated models for the time until the loss of detection that were restricted to the 
participants with any ZIKV RNA in a given fluid and to index participants. Model-derived 
medians were not estimated for saliva and vaginal secretions because of the few positive 
results. All statistical analyses were performed with the use of SAS software, version 9.3.
RESULTS
As of September 21, 2016, we had contacted 414 of the 1258 index participants with 
symptomatic ZIKV infection, as confirmed on RT-PCR assay. Of these participants, 127 
were enrolled in the study. The percentage of index participants who were adults (≥18 years 
of age) was higher among those who were enrolled in the study than among those who were 
not enrolled (92% vs. 74%), and more were male (59% vs. 45%). Of the 195 household 
contacts of the index participants who were screened, 23 (12%) tested positive for ZIKV 
RNA, for a total of 150 prospective participants. All the participants remained under 
prospective observation, with 493 of 549 visits (90%) attended, except for 1 participant who 
withdrew and 2 who were administratively discontinued.
The mean age of participants was 38 years; 44% were female, including 5 who were 
pregnant (Table 1). Four household contacts with positive results were asymptomatic at 
enrollment. Among the 146 participants with signs or symptoms of ZIKV infection at 
enrollment, 92% were enrolled within 1 week after the onset of illness.
ANTIBODY RESPONSE
Anti–ZIKV IgM antibody was detected in at least one specimen obtained from 140 of 143 
participants (97.9%). Only one specimen was collected from each of the 3 IgM-negative 
participants on days 4, 7, and 30 after the onset of symptoms. Details regarding the detection 
of IgM antibody are provided in Figure S1 in the Supplementary Appendix.
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ZIKV RNA IN SERUM
A total of 132 of 150 participants (88.0%) had detectable ZIKV RNA in at least one serum 
specimen (Table 2). Of the 132 participants, 42 (31.8%) had detectable ZIKV RNA more 
than once. (Values for threshold cycle are provided in Fig. S8A in the Supplementary 
Appendix.) The median time until the loss of RNA detection was 14 days (95% confidence 
interval [CI], 11 to 17), and the 95th percentile of time was 54 days (95% CI, 43 to 64) on 
the basis of the Weibull model (Fig. 1A). Results that were obtained with the use of the 
Turnbull model were similar to those obtained with the Weibull model (Fig. S2A in the 
Supplementary Appendix). The number of days after the onset of symptoms at enrollment 
did not influence the time until the loss of ZIKV RNA detection. When the analyses were 
restricted to the 50% of participants who were enrolled within 2 days after symptom onset, 
the median time until the loss of detection was 13 days (95% CI, 10 to 17). Among the 5 
pregnant women, 3 had detectable RNA at 46 days after symptom onset. At the interim 
analysis, 20 of 150 (13.3%) had detectable RNA at their last visit and were still being 
followed. The maximum duration of detection was 80 days after symptom onset in a 
pregnant participant; an estimated 2% had detectable RNA at this time (Fig. S3A in the 
Supplementary Appendix).
ZIKV RNA IN URINE
ZIKV RNA was detected in at least one urine specimen in 92 of 149 participants (61.7%) 
(Table 2). Overall, 15 (10.1%) had detectable RNA in urine but not in serum, whereas 55 
(36.7%) had RNA in serum but not urine. The model-based median time until the loss of 
detection was 8 days (95% CI, 6 to 10), and the 95th percentile of time was 39 days (95% 
CI, 31 to 47) (Fig. 1B).
ZIKV RNA IN SALIVA AND VAGINAL SECRETIONS
Among the 147 participants who were tested, 15 (10.2%) had ZIKV RNA in at least one 
saliva specimen (Table 2). The rate of positivity in these samples was lower than the rate in 
serum and urine at any number of days after symptom onset (Table 3). Similarly, only 1 in 
50 women (2%) had ZIKV RNA in vaginal secretions (at 3 days after symptom onset). All 
the samples were positive in the RNase P control reaction.
ZIKV RNA IN SEMEN
Of 68 eligible male participants, 55 (81%) provided at least one semen specimen. ZIKV 
RNA was present in at least one specimen in 31 participants (56%). Chance-corrected 
agreement of RNA detection was low in paired samples of semen and serum (κ = 0.05; 95% 
CI, −0.05 to 0.16) and samples of semen and urine (κ = 0.11; 95% CI, 0.01 to 0.22). The 
model-derived median time until the loss of RNA detection was 34 days (95% CI, 28 to 41), 
and the 95th percentile of time was 81 days (95% CI, 64 to 98) (Fig. 1C). However, 11 of 55 
participants had ZIKV RNA in semen at their last visit and are still being followed. The 
maximum duration of RNA detection was 125 days after symptom onset; an estimated 4% 
continued to have detectable RNA at that time (Fig. S3C in the Supplementary Appendix).
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TIME UNTIL THE LOSS OF DETECTABLE ZIKV RNA
We also estimated the time until the loss of RNA detection among the participants with any 
ZIKV RNA in a given fluid during follow-up. Among this subset, the model-derived 
estimated percentiles of time until the loss of RNA detection were longer because the 
analyses were limited to participants with continued viral shedding (Figs. S4, S5, and S6 in 
the Supplementary Appendix).
ANALYSES LIMITED TO INDEX PARTICIPANTS
Index participants were more likely to be male than were the 19 symptomatic household 
contacts (59% vs. 42%), to be at least 18 years of age (92% vs. 68%), and to have been 
recruited within 1 week after symptom onset (99% vs. 42%). When the model was limited to 
index participants, the estimated median time until the loss of detection of ZIKV RNA 
decreased by 1 day in serum and urine and increased by 2 days in semen (Fig. S7 in the 
Supplementary Appendix).
INTERMITTENT RNA DETECTION
We observed intermittent ZIKV RNA detection in serum obtained from 15 participants, in 
urine samples obtained from 5 participants, and in semen samples obtained from 3 
participants (Fig. S9 in the Supplementary Appendix). The range of days between positive 
specimens was 14 to 62 in serum, 14 to 35 in urine, and 21 to 36 in semen.
ISOLATION OF ZIKV
ZIKV isolation was attempted in 20 semen specimens with threshold-cycle values ranging 
from 19 to 37 and in 20 serum specimens with threshold-cycle values ranging from 22 to 37. 
Virus isolation was successful in 6 of 20 semen specimens (30%) with threshold-cycle 
values ranging from 19 to 27 and in 1 of 20 serum specimens (5%) with a threshold-cycle 
value of 22.
DISCUSSION
In this preliminary analysis, we obtained data on how long it takes for ZIKV RNA to clear 
among the participants with acute ZIKV infection and detectable ZIKV RNA at enrollment. 
The recruitment of participants was based on an ongoing surveillance platform that enabled 
90% of participants to enroll within the first week after the onset of symptoms, which 
provided increased resolution for ZIKV RNA detection starting soon after symptom onset. 
In our study, half of the participants had detectable viral RNA in urine for at least 1 week 
after symptom onset, in serum for 2 weeks, and in semen for more than 1 month, whereas 
5% or less had detectable viral RNA in urine for 6 weeks, in serum for 8 weeks, and in 
semen for 3 months. Conversely, ZIKV RNA was infrequently detected in saliva and vaginal 
secretions.
The CDC recommends RT-PCR testing of serum and urine samples obtained from 
symptomatic participants less than 14 days after symptom onset.5 Our results contrast with 
the findings of other studies,10,29 which showed more frequent detection of ZIKV RNA in 
urine than in serum. However, the cited studies had small sample sizes that limit 
Paz-Bailey et al. Page 6
N Engl J Med. Author manuscript; available in PMC 2018 August 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
generalizability. The discrepant results may also be explained by differences in the 
population that was included in the analyses. A previous study showed frequent ZIKV RNA 
detection in saliva within 5 days after symptom onset.11 We detected ZIKV RNA 
infrequently in saliva; however, we did not have enough specimens to determine RNA 
detection early after onset.
IgM antibody was detected in almost all ZIKV-infected participants in this study. This 
finding may reflect a primary immune response to ZIKV. However, given the high 
prevalence of previous flavivirus infection in Puerto Rico,32 these results may not be 
generalizable to a population that has not been extensively exposed to flavivirus. The 
usefulness with regard to the specificity of IgM testing for diagnosis of ZIKV in geographic 
areas with discrepant exposure to flavivirus requires further study.
In our study, the observed duration of ZIKV RNA in serum was longer than detection times 
reported for dengue virus. More than 90% of the patients who are infected with any of the 
four dengue viruses clear RNA within 10 days after the onset of symptoms.33 Studies 
involving asymptomatic blood donors with the use of transcription-mediated amplification (a 
technique that is more sensitive than RT-PCR) showed that the median time until RNA 
clearance for West Nile virus was 13 days (95% CI, 12 to 15), an interval that is similar to 
what we observed for ZIKV.34 Since the cross-reactivity of antibodies between flaviviruses 
limits the use of serologic analysis, we recruited participants who had detectable RNA at 
enrollment, a factor that could have contributed to increased times until RNA clearance. 
Although we were able to isolate ZIKV in serum and semen specimens with low threshold-
cycle values, further study is required to determine whether the extended duration of ZIKV 
RNA in serum correlates with infectivity. The minimal time that persons who have potential 
exposure to ZIKV should avoid donating blood is currently 120 days, which covers the 
maximum duration of RNA detection that we observed in our study.35
The CDC recommends that women who have been infected or exposed to ZIKV wait at least 
8 weeks from symptom onset or last exposure before attempting conception.36 In our study, 
95% of the participants no longer had detectable ZIKV RNA in serum at 8 weeks. Although 
these data suggest that the risk of intrauterine transmission among ZIKV-infected women 
who are trying to conceive toward the end of an 8-week period after symptom onset is small, 
we will continue to monitor women of reproductive age to inform evaluations of these 
recommendations.
Despite model-based estimates suggesting that sexual transmission contributes only 
modestly to epidemic propagation,37,38 sexual transmission could complicate efforts to 
prevent the transmission of ZIKV. The CDC recommends that men with possible ZIKV 
exposure, regardless of symptom status, should use condoms or abstain from sex for at least 
6 months.36 Although two case reports detected RNA in semen more than 180 days after 
symptom onset,26,27 such late detection seems infrequent. Our study documented that few 
men have detectable ZIKV RNA past 3 months, and the maximum time that has been 
observed in our study thus far was 125 days.
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Our study has several limitations. By enrolling only participants with positive results for 
ZIKV RNA in urine or serum on RT-PCR assay at baseline and excluding those who were 
IgM-positive only, we may have biased our findings by recruiting persons who have a longer 
duration of ZIKV RNA in serum or urine. However, when our analyses were limited to 
participants who had enrolled within 2 days after symptom onset, our duration estimates 
were similar to those in the overall sample. The detection of ZIKV RNA does not 
necessarily correlate with having infectious virus, a factor that we are studying in additional 
virus-isolation assays. We determined the limit of detection of ZIKV RNA in semen, but we 
were unable to evaluate the sensitivity of the test for saliva and vaginal secretions with a 
similar validation study. However, all semen, saliva, and vaginal swabs tested positive for the 
RNase P internal control reaction, which suggests that the RNA extraction and conditions of 
the assay are probably not reasons for the failure to detect ZIKV RNA in saliva and vaginal 
secretions. Nonetheless, without knowing the limit of the detection of the Trioplex RT-PCR 
assay in these specimen types, negative results should be interpreted with caution. To 
estimate model-derived percentiles for the time until virus clearance at the population level, 
we assumed that all infected participants had ZIKV RNA in all specimens at symptom onset. 
This assumption resulted in shorter median and 95th percentile estimates than if we had 
limited our analyses only to participants with detectable ZIKV RNA. Data that were 
obtained from symptomatic participants may not be generalizable to all persons infected 
with ZIKV.
In conclusion, our study provides a longitudinal assessment of multiple body fluids to 
describe the persistence of ZIKV among infected participants. The results provide 
preliminary evidence that ZIKV is present in serum for a longer period than expected for 
other flaviviruses (e.g., dengue), a finding that may have implications for diagnostic 
recommendations and prevention of transmission.
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Figure 1. Time until the Clearance of Zika Virus RNA in Serum, Urine, and Semen
Shown are models of the time until the loss of Zika virus (ZIKV) RNA detection after the 
onset of symptoms in serum (Panel A), urine (Panel B), and semen (Panel C) obtained from 
150 study participants, as estimated with the use of Weibull regression. To estimate model-
derived percentiles for the time until virus clearance at the population level, we assumed that 
all infected participants had ZIKV RNA in all specimens at symptom onset. Also shown are 
medians and 95th percentiles of the time until the loss of detection, the key values that were 
reported in this preliminary study. Blue shading denotes 95% confidence intervals. Data for 
4 participants who were asymptomatic at the time of enrollment were excluded from the 
Paz-Bailey et al. Page 11
N Engl J Med. Author manuscript; available in PMC 2018 August 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
estimates of the time until the loss of RNA detection, since the number of days after the 
onset of symptoms could not be determined.
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Table 1
Characteristics of the Participants at Baseline.
Characteristic Participants (N = 150)
Age
 Mean (range) — yr 37.8 (<1 to 83)
 Age group — no. (%)
  0–17 yr 17 (11.3)
  18–64 yr 124 (82.7)
  ≥65 yr 9 (6.0)
Female sex — no. (%) 66 (44.0)
Pregnancy — no. (%) 5 (3.3)
Presence of signs or symptoms of Zika virus infection at enrollment — no. (%)
 No* 4 (2.7)
 Yes 146 (97.3)
Days after symptom onset at enrollment — no./total no. (%)
 0–2 days 66/146 (45.2)
 3–5 days 63/146 (43.2)
 6–7 days 5/146 (3.4)
 8–14 days 4/146 (2.7)
 ≥15 days 8/146 (5.5)
Signs or symptoms at enrollment — no./total no. (%)†
 Fever 115/146 (78.8)
 Red eyes or eye pain 119/146 (81.5)
 Rash 135/144 (93.8)
 Pruritus 117/145 (80.7)
 Photophobia 59/144 (41.0)
 Edema 92/145 (63.4)
 Arthralgia 120/139 (86.3)
 Myalgia 102/125 (81.6)
 Headache 115/145 (79.3)
 Abdominal pain 73/145 (50.3)
 Lymphadenopathy 50/144 (34.7)
 Diarrhea 62/145 (42.8)
 Nausea 63/145 (43.4)
 Vomiting 17/145 (11.7)
 Pelvic pain 25/139 (18.0)
 Dysuria 25/145 (17.2)
 Other‡ 129/144 (89.6)
Laboratory findings
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Characteristic Participants (N = 150)
 Median white-cell count (range) per mm3 5200 (2100 to 40,000)
 Median platelet count (range) per mm3 216,000 (80,000 to 373,000)
 Median hematocrit (range) — % 42.2 (30.9 to 51.9)
*
This category includes two participants who were asymptomatic at baseline but in whom signs or symptoms developed within 7 days after 
specimen collection.
†
The median duration of fever was 2 days (range, 1 to 22); red eyes, 3 days (range, 1 to 7); and rash, 5 days (range, 1 to 25).
‡Other signs or symptoms included cough (in 33.1% of the participants), yellow eyes or skin (4.8%), difficulty urinating (7.8%), blood in urine 
(5.5%), painful ejaculation (6.7% of men), and penile discharge (2.7% of men).
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